- Conditions
- Critically-ill
- Interventions
- Thermal-aided muscle activation
- Procedure
- Lead sponsor
- Niveus Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Baltimore, Maryland • Springfield, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 975
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Infections
- Interventions
- Dornase alfa, Placebo
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 7 Days to 4 Months
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Substance Use Disorders, Insomnia
- Interventions
- Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV/AIDS, Diabetes Mellitus, Hypertension, Substance Use
- Interventions
- Patient Navigation
- Behavioral
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Pediatric Patient (1m-21y), ICU Admission, Hyperglycemia
- Interventions
- Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Intracranial Atherosclerotic Disease, Stroke, Angioplasty, Balloon, Hemodynamics, Device Safety
- Interventions
- Submaximal balloon angioplasty
- Device
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stroke
- Interventions
- Forced Rate Exercise + Rehab, Rehabilitation
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- T Cell Lymphoma, T-cell Lymphoma
- Interventions
- Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • New York, New York
- Conditions
- Neuroblastoma
- Interventions
- Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- lomustine, procarbazine hydrochloride, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2018
- U.S. locations
- 95
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Community-Acquired Pneumonia, Antimicrobial Stewardship, Point-of-Care Testing
- Interventions
- Rapid Diagnostic Testing, Pharmacist-led de-escalation
- Diagnostic Test · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28,580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 12
- States / cities
- Vero Beach, Florida • Weston, Florida • Akron, Ohio + 8 more
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- In-Person Patient Education, Commitment to Change, Blood pressure monitoring, Written Patient Education, Text-based reinforcement for CKD self-management, Community-based education session, reinforcement for self-management, Text-based reinforcement for general health self-management
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Premature Birth
- Interventions
- Language Treatment, Control Treatment
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 24 Weeks to 31 Weeks
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Cocaine Dependence
- Interventions
- Intensive Outpatient Treatment, Adaptive telephone-based counseling, Adaptive telephone-based counseling plus incentives
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Self-Injurious Behavior
- Interventions
- Noncontingent Reinforcement (NCR), Combination Treatment
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cocaine Dependence, Cocaine Use Disorder, Opiate Dependence, Opioid-use Disorder, Cannabis Dependence
- Interventions
- Four-Session Mind Freedom Plan, Treatment as usual therapy
- Behavioral
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cardiac Surgery
- Interventions
- OR extubation, ICU extubation
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pneumonia Childhood
- Interventions
- Clinical Decision Support
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 536 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- Sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2007
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 80 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Neurodevelopmental Disorders
- Interventions
- Intensive interdisciplinary therapy
- Other
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 4 participants
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Other Preterm Infants
- Interventions
- HCP will place the Invictus Cranial Support Device (CSD) on the patient, human intervention
- Device · Other
- Lead sponsor
- Invictus Medical, Inc.
- Industry
- Eligibility
- 30 Weeks to 36 Weeks
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- vincristine sulfate, prednisone, doxorubicin hydrochloride, pegaspargase, cytarabine, methotrexate, dexamethasone, etoposide, cyclophosphamide, leucovorin calcium, filgrastim, asparaginase, mercaptopurine
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more